Overview

R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

Purpose: to evaluate an efficacy of chemotherapy regimens R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cells transplantation (auto-SCT) in newly diagnosed patients with DLBCL with intermediate and high risk.

Phase:

Phase 3

Details

Lead Sponsor:

National Research Center for Hematology, Russia

Collaborator:

National Research Center for Hematology

Treatments:

Cyclophosphamide
Doxorubicin
Etoposide
Prednisone
Vincristine